Related Experiment Video
Updated: Mar 21, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.8K
Cell saver processing mitigates the negative effects of wound blood on platelet function
J Gäbel1, C J Malm1,2, V Radulovic3
1Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
Acta Anaesthesiologica Scandinavica
|May 4, 2016
Summary
Cell saver processing of wound blood improves hemostasis by preserving platelet function. This method mitigates negative effects on blood clotting, making retransfusion safer for cardiac surgery patients.
Area of Science:
- Cardiovascular Surgery
- Transfusion Medicine
- Hemostasis and Thrombosis
Background:
- Wound blood from cardiac surgery exhibits poor hemostatic properties.
- Retransfusion of unwashed wound blood may negatively impact patient hemostasis.
- Cell saver processing is investigated as a method to mitigate these effects.
Purpose of the Study:
- To evaluate if cell saver processing of wound blood reduces negative effects on hemostasis.
- To compare the hemostatic properties of processed versus unprocessed wound blood.
Main Methods:
- Wound blood was collected from cardiac surgery patients during cardiopulmonary bypass.
- Blood was processed using a cell saver or left unprocessed.
- Processed and unprocessed blood were added ex vivo to whole blood samples to assess clot formation and platelet function.
Main Results:
- Unprocessed wound blood significantly impaired clot formation and platelet aggregability.
- Cell saver processing did not affect clot formation but completely abolished negative effects on platelet aggregability.
- Adenosine diphosphate-induced platelet aggregation was significantly higher with processed wound blood.
Conclusions:
- Cell saver processing mitigates the negative effects of wound blood on platelet function.
- This processing method improves the safety of wound blood retransfusion.
- Further research may explore optimal processing parameters.
More Related Videos
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
1.3K
12:40Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
29.7K
Related Concept Videos
01:22Formation of the Platelet Plug
10.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.5K
01:05Introduction to Hemostasis
16.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
16.1K
01:16Clot Retraction and Fibrinolysis
10.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.0K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.1K
01:18Structure and Function of Platelets
4.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K